186 related articles for article (PubMed ID: 25732554)
1. Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs.
Gou Y; Zhang Y; Yang F; Liang H
Curr Pharm Des; 2015; 21(14):1848-61. PubMed ID: 25732554
[TBL] [Abstract][Full Text] [Related]
2. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin.
Zhang Y; Ho A; Yue J; Kong L; Zhou Z; Wu X; Yang F; Liang H
Eur J Med Chem; 2014 Oct; 86():449-55. PubMed ID: 25200980
[TBL] [Abstract][Full Text] [Related]
3. HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach.
Yang F; Liang H
Future Med Chem; 2016; 8(2):89-91. PubMed ID: 26824398
[No Abstract] [Full Text] [Related]
4. Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin.
Timerbaev AR; Aleksenko SS; Polec-Pawlak K; Ruzik R; Semenova O; Hartinger CG; Oszwaldowski S; Galanski M; Jarosz M; Keppler BK
Electrophoresis; 2004 Jul; 25(13):1988-1995. PubMed ID: 15237398
[TBL] [Abstract][Full Text] [Related]
5. Understanding the interaction between human serum albumin and anti-bacterial/ anti-cancer compounds.
Rehman MT; Khan AU
Curr Pharm Des; 2015; 21(14):1785-99. PubMed ID: 25738491
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
[TBL] [Abstract][Full Text] [Related]
7. Designing Prodrugs Based on Special Residues of Human Serum Albumin.
Gou Y; Yang F; Liang H
Curr Top Med Chem; 2016; 16(9):996-1008. PubMed ID: 26303424
[TBL] [Abstract][Full Text] [Related]
8. Binding of the anticancer drug BI-2536 to human serum albumin. A spectroscopic and theoretical study.
Fernández-Sainz J; Pacheco-Liñán PJ; Granadino-Roldán JM; Bravo I; Garzón A; Rubio-Martínez J; Albaladejo J
J Photochem Photobiol B; 2017 Jul; 172():77-87. PubMed ID: 28531794
[TBL] [Abstract][Full Text] [Related]
9. Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin.
Wang Y; Wang X; Wang J; Zhao Y; He W; Guo Z
Inorg Chem; 2011 Dec; 50(24):12661-8. PubMed ID: 22077361
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the binding of an anticancer drug, lapatinib to human serum albumin.
Kabir MZ; Mukarram AK; Mohamad SB; Alias Z; Tayyab S
J Photochem Photobiol B; 2016 Jul; 160():229-39. PubMed ID: 27128364
[TBL] [Abstract][Full Text] [Related]
11. Interactive association of drugs binding to human serum albumin.
Yang F; Zhang Y; Liang H
Int J Mol Sci; 2014 Feb; 15(3):3580-95. PubMed ID: 24583848
[TBL] [Abstract][Full Text] [Related]
12. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
[TBL] [Abstract][Full Text] [Related]
13. Albumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers.
Ishima Y
Biol Pharm Bull; 2017; 40(2):128-134. PubMed ID: 28154250
[TBL] [Abstract][Full Text] [Related]
14. Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin.
Gou Y; Zhang Z; Qi J; Liang S; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Dec; 153():13-22. PubMed ID: 26398432
[TBL] [Abstract][Full Text] [Related]
15. Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin.
Ang WH; Daldini E; Juillerat-Jeanneret L; Dyson PJ
Inorg Chem; 2007 Oct; 46(22):9048-50. PubMed ID: 17918830
[TBL] [Abstract][Full Text] [Related]
16. Is the Sudlow site I of human serum albumin more generous to adopt prospective anti-cancer bioorganic compound than that of bovine: A combined spectroscopic and docking simulation approach.
Joshi R; Jadhao M; Kumar H; Ghosh SK
Bioorg Chem; 2017 Dec; 75():332-346. PubMed ID: 29096094
[TBL] [Abstract][Full Text] [Related]
17. The anticancer activity and HSA binding properties of the structurally related platinum (II) complexes.
Yousefi R; Aghevlian S; Mokhtari F; Samouei H; Rashidi M; Nabavizadeh SM; Tavaf Z; Pouryasin Z; Niazi A; Faghihi R; Papari MM
Appl Biochem Biotechnol; 2012 Jun; 167(4):861-72. PubMed ID: 22622643
[TBL] [Abstract][Full Text] [Related]
18. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
[TBL] [Abstract][Full Text] [Related]
19. Anticancer metallotherapeutics in preclinical development.
Kaluderović GN; Paschke R
Curr Med Chem; 2011; 18(31):4738-52. PubMed ID: 21919843
[TBL] [Abstract][Full Text] [Related]
20. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
